LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
NASDAQ:LVTX
Price:
1.09
USD
0.93%
Market Closed
Market Cap:
28.7m
USD
LAVA Therapeutics NV
Tax Provision
|
LAVA Therapeutics NV
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Tax Provision
-$279k
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Tax Provision
-$3.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Tax Provision
€197k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Tax Provision
-$2.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
argenx SE
XBRU:ARGX
|
Tax Provision
$747.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Tax Provision
-$8.2m
|
CAGR 3-Years
-224%
|
CAGR 5-Years
-112%
|
CAGR 10-Years
N/A
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
LVTX
Intrinsic Value
2.02
USD
Undervaluation 46%
See Also
What is LAVA Therapeutics NV's Tax Provision?
Tax Provision
-279k
USD
-279k
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Tax Provision amounts to -279k USD.
What is LAVA Therapeutics NV's Tax Provision growth rate?
Tax Provision CAGR 3Y
-91%
-91%
Over the last year, the Tax Provision growth was -12%. The average annual Tax Provision growth rates for LAVA Therapeutics NV have been -91% over the past three years .
You don't have any saved screeners yet